Crispr Therapeutics: Controlled risk for accelerated development

The ex vivo direction that Crispr Therapeutics first took with its gene editing technology may have been the safest path among the available alternatives, but it was far from de-risked. From the need to establish CMC protocols upfront to controlling for risk at each level of the indication selection process, the company created a road map for successful therapeutic platform technology execution.

Rodger Novak, founding CEO of Crispr Therapeutics AG (NASDAQ:CRSP) told BioCentury that there was nothing safe or boring about the biotech’s decision to initially pursue ex vivo stem cell editing. But he believes it was the rational decision for developing the technology...